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Abstract 
Adverse effects are a significant factor that determine how long patients will tolerate a 
given antiretroviral drug regimen.  They also influence treatment options, and play an 
important role in the much needed adherence to treatment by patients on Highly Active 
Antiretroviral Therapy (HAART).  This study is aimed at understanding adverse effects 
experienced by patients on the first line antiretroviral therapy at Keetmanshoop Hospital 
in Namibia.  Methods: A retrospective quantitative method was used to review records 
of patients on first line antiretroviral treatment who started treatment between November 
1st 2007 and December 1st, 2008 and followed up until they reached 36 – 48 months on 
treatment.  Records of 94 patients were found eligible to be included in the study.  Data 
was analysed using Stata 12 data analysis software.  Results:  The most reported 
adverse effect was musculoskeletal disorders (25%) whereas headache (16%) was the 
least reported.  Low haemoglobin (78%) was the most common recorded hematologic 
adverse effect whereas low red cell distribution width and low mean platelet volume 
were the least recorded adverse effects (0%).  A Male patient was more likely to 
experience a low haemoglobin levels compared to a female patient (adjusted OR: 3.29, 
95% CI: 1.3 – 8.3).  A male patient was found to be 64% times less likely to experience a 
higher mean cell haemoglobin compared to a female patient (adjusted OR. 0.31, 95% 
CI: 0.11 – 0.87).  A patient on nevirapine was more likely to experience an elevated 
creatinine level compared to a patient on efavirenz (adjusted OR; 36.0, 95%CI: 2.02 – 
62.5).  At baseline, a patient who had prior exposure to ART had an 81 times (adjusted 
OR: 81.4, 95%CI: 5.3 – 119, p-value=0.00) increased odds of experiencing a high mean 
cell volume (MCV) compared to a patient with no ART exposure.  A patient with a higher 
CD4 count was also less likely to experience a low hemoglobin compared to a patient 
with low CD4 count (adjusted OR; 0.31, 95% CI: 0.12 – 0.77).  The author recommends 
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further studies with higher sample size to confirm whether higher creatinine levels are 
more prevalent in patients on nevirapine compared to patients on efavirenz; this will 
have clinical implications especially in patients with impaired renal system.  Antiretroviral 
treatment increases chances of developing macrocytosis anaemia; clinical implication of 
this condition may need to be investigated.  
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Chapter 1: Study overview  
1.1. Introduction 
With the scourge of HIV infections still on the increase, antiretroviral medications 
(ARVs) have brought relief to many people.  Many lives are being saved and many 
HIV positive people enjoy healthy productive lives.  However there are challenges 
related to this phenomenon, among others, the need to maintain patients on effective 
ARV regimens.  Adverse effects are among others, a significant factor that determine 
how long a patient will tolerate a given ARV regimen, influence treatment options, 
and also plays an important role in the much needed adherence to treatment by a 
patient.  For this reason there is always need for further information in the field of 
adverse effects associated with ARVs. 
 
This document discusses a study done at Keetmanshoop Hospital‟s ARV clinic.  The 
study is discussed in terms of objectives, literature review, methods used in the 
study, results, discussion of results, conclusions and recommendations.   
1.2. About Keetmanshoop and Namibia 
The Keetmanshoop district hospital is one of the main referral public health facilities 
in the Karas Region with an estimated catchment population of about 38 865.  The 
district has an estimated HIV prevalence rate of about 12.4, (Ministry of Health, 
2013).  The ARV clinic in the district was opened in 2003, by February 2011, a 
cumulative number of about 2 640 patients were enrolled into HIV, of which 1413 
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were on Highly Active Antiretroviral Therapy (HAART).  According to hospital based 
statistics, about 619 patients have been on treatment for a continuous period of four 
or more years, which made these clients eligible to be included in the criteria set for 
this study. 
The first line ARV regimen in Namibia includes Tenofovir (TDF), Lamivudine (3TC) 
and Nevirapine (NVP) or Efavirenz (EFV), with first line alternatives of Zidovudine 
(AZT), 3TC and EFV or NVP (Ministry of Health, 2010). 
1.3. Significance of the research 
A lot is known about the types and expected adverse effects of different ARV 
regimens from clinical trials and various experiences in the field.  Outside or 
confounding factors such as nutrition, geographical location, genetic influences and 
people‟s habits could easily cause some variation in trends of how adverse effects 
are experienced.  According to the World Health Organisation, (WHO, 2007), some 
factors that make ARV toxic profiles to be less well known in the developing world 
include, existence of co-morbidities, malnutrition, reliance on local alternative or 
traditional medicines, level of training of the human resources managing patients on 
ARVs, non-existence of medicine safety regulatory systems etc.  Given these facts it 
can be concluded that some adverse effects of medications remains unknown, and 
therefore it becomes significant to carry out a study of this nature despite the 
available information. 
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1.4. Aim of the study 
This study is aimed at finding out the prevalence and type of adverse effects 
(reported, hematologic, hepatic and renal function related adverse effects) 
experienced by patients on the first line ARVs treatment as ascertained and 
documented by health care providers at Keetmanshoop Hospital.  The study also 
aimed at assessing the risk factors for development of adverse effects in HIV-
positive patients on antiretroviral therapy (ART).  
1.5. Study objectives 
Specific objectives of this study were: 
1. To determine the prevalence of adverse effects (reported, hematologic, hepatic 
and renal function related adverse effects) related to first line ART.  
2. To find out any association between adverse effects and any of the following 
factors: patient gender, drugs used, treatment duration, patient age and stage of 
HIV infection.  
1.6. Research questions 
The study sought to answer the following questions:   
a) What is the prevalence of adverse effects in patients on first line ART? 
b) Is there any association between adverse effects and gender? 
c) Which adverse effects are drug specific?  
d) Is there any association between the duration of treatment and adverse 
effects?  
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e) Is there any association between patient age and adverse effects?   
f) Is there any association between HIV infection stage and adverse effects?  
1.7. Hypotheses 
The following hypotheses were tested using various statistical tests. 
1. (a) Adverse effects experienced by male patients are different from adverse 
effects experienced by female patients. 
(b) There is no difference in the types of adverse effects experienced by male 
and female patients on first line ART.  
2. (a) Patients on nevirapine based treatment are at an increased risk of 
developing adverse effects compared to patients on efavirenz based 
treatment of the first line drugs.  
(b) There is no difference in adverse effects experienced between nevirapine 
based and efavirenz based ART treatment.   
3.  (a) Patients who are longer on ART treatment are at increased risk of   
experiencing adverse effects compared to patients with shorter treatment 
durations. 
 (b) There is no association in the risks of experiencing adverse effects and 
treatment duration.      
4. (a) Older patients on first line ART drugs are more prone to experiencing  
adverse effects than younger patients.   
         (b) Older patients on first line ART drugs are not prone to experiencing adverse 
effects compared to younger patients.  
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5. (a) Patients with advanced HIV infection are more likely to experience adverse 
effects compared to patients with less advanced HIV infection.  
         (b) There is no difference in the adverse effects experienced by patients with 
advanced and less advanced HIV disease.   
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Chapter 2: Literature review  
2.1. Overview 
Literature review was done to reveal what exists on the topic.  Little information was 
found on the topic from Namibia and none from Keetmanshoop.  Many studies from 
Africa and the international community are available.  
2.2. Adverse effects lead to low adherence to antiretroviral medications 
A study carried out at Katutura Health Centre in Windhoek, the capital city of 
Namibia, using questionnaire and interviews by the University of Namibia and the 
University of Toronto (2007), revealed that factors leading to none adherence and 
suboptimal adherence has multiple causes.  However this qualitative study does not 
give indication as to which causes were found to be most common or ranked the 
highest.  Factors affecting adherence were categorised as patient factors and 
healthcare worker factors.  Minor side effects were among other factors mentioned 
as causes that can lead to suboptimal adherence.  Similar findings were ascertained 
in Botswana by Kip et al. (2009).  A study done on clients taking ARVs in selected 
towns of Namibia by Ibis Namibia, Lironga Eparu and the Rainbow Project (2005), 
ascertained that about 57% of clients interviewed had at one point or the other 
experienced adverse effects.  This study also ascertained that 20% of these clients 
had found adverse effects bad enough leading them to stop taking ARV medicines. 
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There is increasing evidence that nutrition is one of the common factors affecting 
adherence to ARV medications.  This is evidenced by many studies conducted on 
adherence mostly in the resource constrained areas of Southern African (Hardon et 
al, 2006; The Global HIV/AIDS news 2009).  Clients will usually not take ARV 
medicines if there is inadequate food due to fears of exacerbating adverse effects. 
Issues leading to suboptimal adherence are consistent in many studies but varied in 
ranking from place to place.  For example, whereas side effects were reported to be 
less significant in influencing adherence to ART in the Botswana study (Hardon et al. 
2006; Kgatlwane, 2004), it was reported to be one of the first reasons for suboptimal 
adherence in studies conducted in Zambia and Tanzania respectively (Hardon et al. 
2006; Murray et al. 2007). A study by Woldemedhin and Wabe (2012), found that 
67% of the patients who had their treatment modified was due to adverse effects.  
 
This all point to the significance that adverse effects have on HIV treatment.  As 
pointed out in the above studies there is evidence that depending on other external 
factors such as nutrition, genetic, geographical differences and type of study, there 
could be differences in the way adverse effects are experienced from one place to 
another. 
2.3. Pharmacology of 1st line antiretroviral drugs  
The following are pharmacological terms used to describe the reactions and effects 
that can result from the use of various medications, their inclusion here is made for 
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clarification purposes and to enhance understanding of the context under which they 
are used in this section.  
Adverse drug reaction 
Refers to a response related to drug or medicinal product that is harmful or 
unpleasant, which predicts hazard from future use and warrants prevention or 
specific treatment, or alteration of the dosage regimen or product withdrawal 
(Edwards and Aronson, 2000). 
Adverse effects 
Is a more mild and encompassing term that refers to all unwanted outcomes 
attributed to some action of the drug (Edwards and Aronson, 2000). 
Adverse events 
Adverse events on the other hand, are adverse outcomes occurring at the same time 
a patient is taking the drug, which is not or not necessarily attributable to the drug 
(Edwards and Aronson, 2000). If an adverse event is attributable to a drug it 
becomes a suspected adverse drug reaction (Aronson, 2009). 
Side effect 
Is an expected and known outcome resulting from the use of a drug which happens 
not to be the intended therapeutic effect of that drug (Edwards and Aronson, 2000). 
They are predictable and undesired therapeutic effects of a drug occurring at normal 
therapeutic dose ranges (S Buys Training and Development Academy 2007).  The 
Medical dictionary (2012) states that, pharmacological side effects are true drug 
effects.  Side effects may be related or unrelated to the mechanism of the drug being 
administered and may be dose related or not (Edwards & Aronson, 2000).  Side 
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effects can also be wanted or unwanted effects from medicines (Edwards & 
Aronson, 2000). 
Toxic effects (drug toxicity) 
A toxic effect is a response to a drug which is harmful to the health or life of an 
individual (Medical dictionary 2012).  Toxic effects are related to the main 
pharmacologic action of the drug e.g. bleeding with anticoagulant or unrelated e.g. 
liver damage from Paracetamol (Rang et al. 2012).  Toxic effects are usually an 
exaggeration of the expected therapeutic effects that rarely occurs at normal doses 
(Edwards & Aronson, 2000). 
Secondary effects 
Are undesired effects produced in addition to the pharmacologic effects of the drug 
(Nursing buddy 2012).   
Hypersensitivity reactions 
Hypersensitivity reactions are unpredictable and abnormal reactions occurring with 
the use of medicines.  These reactions can be divided into, allergic, paradoxical and 
genetic anomalies (S Buys Training and Development Academy 2007).   
Idiosyncratic reaction 
Is a reaction that occurs in a small number of persons and does not correlate to 
dosage or means of therapy (Uetrecht and Naisbitt, 2013; The free dictionary 2012). 
Drug interaction 
Refers to the modification of the effect of a drug by another drug or drugs, the 
modification could be negative or positive and can result from concurrent 
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administration of drugs, herbs, medications, nutritional supplements or disease (The 
free dictionary 2012). 
Drug antagonism 
Refers to the drug interaction situation where one drug‟s effect is reduced, 
completely cancelled out or enhanced by the presence of another drug (Rang et al. 
2012). 
Chemical antagonism 
Refers to a situation where two substances combine in a solution and results in the 
loss of the effects of one or both drugs (Rang et al. 2012).   
Pharmacokinetic antagonism 
Refers to the reduction in concentration at the site of action of one drug by another, 
this can be by metabolic degradation, absorption and excretion interferences (Rang 
et al., 2012). 
Competitive antagonism 
Refers to a situation where an antagonist and agonist drugs with similar affinity for a 
receptor, competes for the occupancy of the receptor, however in this situation, 
raising the level of the agonist can restore its effect (Rang et al. 2012).  
Non-competitive antagonism (Interruption of receptor – effector linkage) 
Refers to a situation where an antagonist binds to a site different from the agonist 
but influences the effect of the agonist by reducing its binding or effect (Rang et al. 
2012). 
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Physiologic antagonism 
Describes a situation where two drugs with opposing effects tend to cancel each 
other‟s effect out (Rang et al. 2012). 
Terminology scope of use in this study 
Hematological, liver and renal function profile abnormalities in this study were 
classified as adverse effects.  There is evidence that many of the adverse effect 
ascertained by the study will fall in the „possible‟ adverse drug reaction range of the 
Naranjo assessment scale (Doherty, 2009), however the limitations in the study 
methodology makes it difficult to establish causality.  The classification of 
hematological, liver and renal function profile abnormalities as adverse effects is 
therefore assumed based on the Naranjo assessment scale which is mostly based 
on the available supporting literature.      
2.3.1. List of drugs 
The first line ARV regimen in Namibia include Tenofovir (TDF), Lamivudine (3TC), 
Nevirapine (NVP), Efavirenz (EFV), Zidovudine (AZT), (Ministry of Health 2010).  
Stavudine (D4T) is also part of the first line ARV medications.  However, due to its 
undesirable adverse effects such as lipodystrophy, it is no longer recommended to 
be taken for over two years (Ministry of Health 2010).  D4T is excluded from the 
discussions below as the reason given above does not allow it to be part of this 
retrospective study.  The following first line ARV regimen combinations are 
recommended; (TDF/3TC/EFV), (TDF/3TC/NVP), (AZT/3TC/EFV), (AZT/3TC/NVP).  
Second line drugs which are not part of this study include: (AZT/TDF/3TC/LPV/r) 
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with the addition being Lopinavir boosted with Ritonavir (LPV/r) (Ministry of Health 
2010). 
2.3.2. Zidovudine   
(i) Mechanism of action  
Zidovudine (AZT) is a nucleoside reverse transcriptase inhibitor prodrug which acts 
as a false substrate for the reverse transcriptase enzyme and terminates the DNA 
chain (University of Cape Town 2012). In other words, the synthetic thymidine 
analogue from the AZT competes with the endogenous nucleoside for use by the 
HIV reverse transcriptase enzyme.  The use of the synthetic nucleoside results in the 
termination of the viral DNA which then terminates the infection process (Rang et al. 
2012). 
 
(ii) Pharmacokinetics  
Zidovudine is metabolised in the liver to inactive glucuronide, about 20% of the 
active form is excreted in the urine (Rang et al. 2012).  The plasma half-life is about 
one hour; the intracellular half-life is three hours (Rang et al. 2012).  
  
(iii) Adverse effects  
Some of the common adverse effects of AZT include severe anaemia, neutropenia 
and lactic acidosis (WHO, 2008).  Other adverse effects of this drug are presented in 
appendix 3. 
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(iv) Drug - drug interactions  
Significant drug interactions of ARVs with other medications are well documented.   
It is noted that, many interactions will occur between ART and various medications 
used in the treatment of opportunistic infections and short-term illness, such as short 
courses of antibiotics.  For the sake of this study focus is made on the drug 
interactions that are likely to be encountered in the study, such as interaction with 
anti-tuberculosis medications and other common opportunistic infection treatments 
and prophylaxes such as cotrimoxazole. 
 
The majority of the first line ARV medicines are Nucleoside Reverse Transcriptase 
Inhibitors (NRTI), and generally NRTIs have lower drug interaction profiles than the 
NNRTIs which mostly use the CYP450 system for metabolism (Ministry of Health 
2010). One of the common medications likely to be administered with AZT is 
cotrimoxazole. Cotrimoxazole is given as a standard prophylaxis for opportunistic 
infections such as bacterial pneumonia, bacteria diarrhoeas, etc. (Ministry of Health 
2010).  Co-administration of AZT and cotrimoxazole has been shown to increase 
bone marrow suppression, hence the need to monitor such clients (Pham and 
Flexner, 2005).  There have been reports of a decrease in the area under the serum 
drug concentration-time curve (AUC) of AZT when used together with rifampicin a 
common anti-tuberculosis medication.  However, this decrease is reported to have 
unknown clinical effect (Pham and Flexner, 2005), and therefore no dosage 
adjustments are recommended (Burman, Gallicano and Peloquin, 1999).  Another 
common medication likely to be given to clients on the first line ART is fluconazole 
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given as a secondary prophylaxis to clients who suffer from cryptococcal meningitis 
(Ministry of Health 2010).  A slight increase in AZT serum levels is expected when 
co-administered with fluconazole; however this interaction is described as clinically 
insignificant (Pham and Flexner, 2005).  The risk of Immune Reconstitution 
Syndrome (IRIS) is increased with the co-administration of AZT, nevirapine, 
efavirenz and lamivudine (Medscape Reference 2011).  IRIS is a dramatic increase 
in the inflammatory response to antigens from untreated or partially treated 
infections, occurring in the first few weeks of treatment with HAART (Ministry of 
Health 2010).  Symptoms are a mimic of the particular untreated infections while the 
body undergoes robust improvement in the Immune system (Ministry of Health 
2010).  Patients may experience accelerated liver damage following Immune 
reconstitution (Ministry of Health 2010).  
 
(v)  Drug - food interactions  
Drug food interactions are a common occurrence in people taking HIV medications.  
Drug food interaction can take place through the pharmacodynamic phase as well as 
the pharmacokinetic phase (Rang et al. 2012).  According to Rang et al. (2012), 
medications that increase gastric motility and vice versa influence how much of the 
drug will be absorbed.  Nausea, vomiting and diarrhoea being common side effects 
of many ARV drugs (University of Cape Town 2012), will not only lead to less 
absorption of food nutrients but also influence client‟s adherence to medications.  
Generally, the presence of food in the GI tract can influence the absorption of 
medications into the system and while as some foods such as grapefruit can inhibit 
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the Cytochrome (CYP) 450 3A4 enzymes (Pronsky and Crowe, 2004).  Such an 
inhibition could lead to increased levels of drugs metabolised by CYP 450 system in 
the body resulting in increased adverse effects or toxicity.  There are significant 
interactions between many HIV drugs, however only drugs in the first-line ARV 
treatments are included here. 
 
A liquid fatty meal has been shown to decrease the AUC of AZT by 57%, however its 
clinical significance is unknown, and therefore administration with food is 
recommended as it improves tolerability (Pham and Flexner, 2005). 
 
(vi) Drug - disease interactions  
Drug disease interaction refers to a situation in which medications have potential to 
make a pre-existing disease or condition worse (Lindblad et al. 2005).  HIV infected 
patients can have various pre-existing conditions such as hypertension, diabetes, 
etc., which have potentials of interacting with anti-retroviral therapy.  It is well 
acknowledged from the literature, besides pre-existing conditions that can be made 
worse by ARV medications, that HIV can also affect various organs in the body 
which in turn can have many interactions with drugs.  Short term and long terms 
effects of ART can cause structural changes in the body and worsen other conditions 
or diseases a person may encounter before or after being diagnosed with HIV.  For 
the sake of this study, focus will be on conditions that are likely to be exacerbated by 
the use of ART based on the most eminent and common adverse effects of the 
drugs under study i.e. first line treatment.  
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HIV associated opportunistic infections can lead to condition such diarrhoea and 
malnutrition.  Diarrhoea can in turn limit the absorption of ARVs (Burman, Gallicano 
and Peloquin, 1999) thus leading to medication sub-therapeutic levels.  This 
condition can also be exacerbated by medications whose adverse effect is 
diarrhoea.  Although there seems to be unreliable methods of measuring 
malabsorption, gastro-intestinal disturbances and low CD4 counts have been 
associated with significant malabsorption (Burman, Gallicano and Peloquin, 1999).  
Some conditions that usually affect people living with HIV that often result in drug 
malabsorption include HIV-related achlorhydria, HIV enteropathy, and opportunistic 
infections such as cryptosporidiosis (Burman, Gallicano and Peloquin, 1999).  This 
situation warrants a high index of suspicion from clinicians in patients with advanced 
HIV disease (Burman, Gallicano and Peloquin, 1999).   
 
Skin conditions are also common among patients with HIV, a study by Serge et al. 
(1993) Using review of records found that skin manifestation in the HIV infected 
population were higher than in their non HIV infected counterparts, and that skin 
disorders increased as the disease progressed.  Once a diagnosis of skin infections 
is made, the patient often needs drug therapy, which in turn poses a risk for drug 
skin eruptions (Serge et al.1993).  From this study it can be seen that proper clinical 
judgement will need to be made to ascertain if the cause of a skin condition is related 
to skin infection or drug adverse effects.    
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HIV is also associated with an increased risk of psychiatric disorders, including 
depression, mania, psychosis, and substance abuse (Treisman, 2002).  Zidovudine 
has been associated with mania shortly after its initiation, even occurring in patients 
without any psychiatric history (Treisman, 2002).  Besides the increased risk of 
psychiatric disorders caused by ARVs; complications of HIV may also lead to 
psychiatric disorders.  Among these, are opportunistic infections of the Central 
Nervous System (CNS), tumors, systemic and advanced disease (Treisman, 2002).  
Zidovudine and efavirenz not only have good CNS penetration but also have 
adverse effects that affect the CNS (Treisman, 2002).  This situation may be difficult 
to judge as to what the cause of the CNS condition is related to, and what 
medication to use under such occurrence.  This dilemma will also need to be 
considered when HAART is being used in a patient with pre-existing psychiatric 
disorder.   
 
One of the common complications of HIV is anaemia.  Anaemia is reported to be 
affecting about 60 to 80 percent of people living with HIV especially in the late stages 
of the disease (Friel and Scadden, 2011).  It is also reported to be associated with 
faster progression to AIDS (Sullivan et al. 1998).  According to Subbaraman et al. 
(2009), a study done in India in which blood samples were collected from HIV 
positive patients showed that; 41% had anaemia, and of the anaemic patients, 20% 
had CD4 counts above 500 mm3 and 64% had CD4 counts below 100 mm3.  
Unexplained anaemia is classified as stage 3 under the World Health Organisation‟s 
HIV clinical staging (WHO, 2007).  Causes of anaemia in HIV infected patients are 
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varied and may range from changes in cytokine production with subsequent effects 
on hematopoiesis, opportunistic infections, chemotherapeutic agents such as 
zidovudine and trimethoprim-sulfamethoxazole, cancers, autoimmune destruction of 
red blood cells etc. (Sullivan et al. 1998).  To ensure that there is no exacerbation of 
anaemia, the Ministry of Health in Namibia, recommends that HIV positive clients be 
assessed for anaemia before commencement of treatment with AZT, only clients 
with haemoglobin levels above 8 gm/dl can start such a treatment with periodic 
monitoring (Ministry of Health 2010). 
2.3.3. Tenofovir   
(i) Mechanism of action 
Tenofovir is a new addition to the first line ARVs, it is not included in this study due to 
fewer number of patients placed on it. Its inclusion here is made for completion 
purposes only.  Tenofovir is an analogue of adenosine (University of Cape Town 
2012) and falls under the category of nucleoside reverse transcriptase inhibitors.  It 
is different from most of the NRTIs because it is monophosphorylated making it to be 
called a nucleotide reverse transcriptase inhibitor.  Tenofovir‟s mechanism of action 
is similar to all NRTIs.  It acts as a synthetic building block of the HIV DNA synthesis   
(Hoffman, Rockstroh and Kamps, 2007). 
 
(ii) Pharmacokinetics  
Bioavailability of tenofovir is about 25% fasting and increased to 40% with a high fat 
meal and largely excreted unchanged in the urine through glomerular filtration and 
tubular secretion.  The plasma half-life of tenofovir is about 17 hours (University of 
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Cape Town 2012) and it is not metabolised by the P450 system (Medscape news 
2012). 
 
(iii) Adverse effects  
Adverse effects of tenofovir are presented in appendix 3. 
 
(iv) Drug - drug interactions  
Serum levels of tenofovir can be increased by drugs that reduce renal functions such 
as acyclovir, ganciclovir etc. (University of Cape Town 2012).  In this instances 
caution should be observed when co-administration is warranted. 
 
(v) Drug - food interactions  
Bioavailability of tenofovir is about 25% fasting and increased to 40% with a high fat 
meal (University of Cape Town 2012), except for the changes in bioavailability no 
other significant food interactions were found.  
 
(vi) Drug - disease interactions  
       Another common complication of the HIV infection is HIV nephropathy.  Renal 
disorder can occur at any stage of the HIV infection and ranges from electrolyte 
imbalances to end-stage renal disease (Choi and Rodriguez, 2008).  HIV associated 
nephropathy (HIVAN) has been demonstrated in about 60% of the black race living 
with HIV, and almost none existence in whites (Szczech, 2007).  According to 
Szczech (2007), the pathophysiology of HIV associated nephropathy is likely to be 
 
 
 
 
- 20 - 
 
related to direct uptake of the HIV into certain cells of the kidney.  Improvements 
have been reported after HAART is started, whereas higher viral load and low CD4 
counts are linked to faster progression of the HIVAN (Szczech, 2007).  Symptomatic 
HIVAN is classified as a stage four condition under the WHO clinical staging for HIV 
(WHO 2007).  Apart from HIVAN, there are other primary kidney diseases 
associated with HIV such as IgA nephropathy, Immune-complex glomerulonephritis, 
amyloidosis etc. (Szczech, 2007).  Medications such as tenofovir, adefovir, and 
cidofovir, aminoglycoside antibiotics, acyclovir, and amphotericin etc., have all been 
associated with acute tubular necrosis in HIV-positive patients (Choi and Rodriguez, 
2008).  In Namibia, tenofovir whose major adverse effect is nephrotoxicity (University 
of Cape Town 2012) is part of the first-line of anti-retroviral therapy (Ministry of 
Health 2010).  There is therefore a need to assess the renal function of a patient 
before tenofovir is prescribed.  Ministry of Health (2010) recommends a six monthly 
creatinine clearance monitoring for clients on a tenofovir based regimen.  Caution 
and close monitoring should be exercised when tenofovir is to be used in clients with 
renal insufficiencies (Ministry of Health 2010).  Clients with renal impairment are 
generally at risk of toxicities when NRTI are used, this warrants a need for close 
monitoring (Drug Information Online 2012).   
       2.3.4. Lamivudine 
(i)  Mechanism of action 
Lamivudine (3TC) undergoes anabolic phosphorylation by intracellular kinases to 
form lamivudine 5 triphosphate an active anabolite (Johnson et al. 1999).  
Lamivudine is also a nucleoside reverse transcriptase inhibiting substance.  Its 
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mechanism of action resembles the one described above under AZT but differs in 
that; it is an analogue of cytosine (Rang et al. 2007).  
  
(ii) Pharmacokinetics  
Lamivudine has a high oral bioavailability reaching maximum serum concentrations 
usually within 0.5 to 1.5 hours after the dose (Johnson et al. 1999).  The absolute 
bioavailability is approximately 82% and 68% in adults and children respectively; 
about 70% of an oral dose is eliminated unchanged by kidneys (Johnson et al. 
1999).  And about 5-10% of the drug is excreted as inactive trans-sulfoxide 
metabolite (Johnson et al. 1999; Pharmacogenomics. Knowledge. Implementation, 
2012). 
 
(iii) Adverse effects 
Adverse effects of lamivudine are presented in the appendix 3. 
 
(iv) Drug - drug interactions  
No clinically significant interaction of this medicine is documented by Pham and 
Flexner (2005) and the University of Cape Town (2012).  The Mediscape Reference 
(2011) highlights the increased risk of Immune Reconstitution Inflammatory 
Syndrome when lamivudine is used in combination with any of AZT, nevirapine or 
efavirenz drugs.  Many other drug interactions of lamivudine listed by the Drug 
Information Online (2012), leading to risks of hepato-toxicity are not likely to be 
encountered in the scope of this study. 
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Pham and Flexner (2005) reported an increase in the 3TC area under the plasma 
drug concentration-time curve (AUC) by 44% if co-administered with cotrimoxazole 
but also indicated this effect as clinically non-significant.  Trimethoprim has also 
been shown to decrease the renal clearance of 3TC whereas 3TC does not have the 
same effect on trimethoprim (Johnson et al. 1999).   
 
(v) Drug - food interactions  
Limited information was found on the interaction between lamivudine and food. 
According to Johnson et al. (1999), food does not seem to alter the AUC of 
lamivudine. 
 
(vi) Drug - disease interactions  
 Patients with known risk factors for pancreatitis should be monitored closely if on 
3TC and discontinuation of 3TC should be done promptly if signs and symptoms 
suggestive of pancreatitis occur (Drug information online 2012). In patients with 
hepatitis, there is a risk of rebound hepatitis following withdrawal of lamivudine 
(University of Cape Town 2012). 
2.3.5. Nevirapine 
(i)  Mechanism of action 
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor, and works by 
attaching to the viral reverse transcriptase enzyme and denatures it; this in turn 
stops the progression of the virus replication (Rang et al. 2012). 
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(ii) Pharmacokinetics  
Nevirapine has a bioavailability of about 90%; the plasma half-life is about 45 hours 
which is reduced by auto-induction to 20 – 30 hours.  It is heavily metabolised in the 
liver by the cytochrome P450 system (Rang et al. 2012; University of Cape Town 
2012).  Metabolites are renally excreted (Rang et al. 2012; University of Cape Town 
2012).   
 
Nevirapine is 60% plasma protein bound and its elimination is mainly through 
oxidative metabolism involving CYP3A and CYP2B6 enzyme (Chou et al. 2010).  
Both CYP3A4 and CYP3A5 share substrates, and whether this is the case in 
nevirapine metabolism, it is not clearly defined (Chou et al. 2010).  Nevirapine is both 
an inducer and a substrate of the CYP 3A4 enzymes (HIV guidelines 2012). 
 
(iii) Adverse effects 
Adverse effects of nevirapine are presented in appendix 3. 
 
(iv) Drug - drug interactions  
Nevirapine and rifampicin are not given together in accordance with the Ministry of 
Health and Social Services in Namibia ART guidelines (2010).   This is because of 
the resulting interaction that leads to reduced nevirapine level from the enzyme 
induction capabilities of the rifampicin (Lalloo, 2009).   Another drug likely to be given 
with nevirapine is fluconazole.  There is an elevated risk of hepatitis occurring as a 
result of increased serum levels of nevirapine caused by fluconazole which inhibits 
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the P450 system (University of Cape Town 2012). This potential adverse effect 
should be monitored in cases of nevirapine and fluconazole co-administration (Pham 
and Flexner, 2005).  Serge et al. (1993), reports more drug eruption being mostly 
related to cotrimoxazole therapy, a situation that also needs to be assessed careful 
in case cotrimoxazole is given concurrently with other medicine that can cause drug 
eruptions such as nevirapine. 
 
Although no dose adjustment is required in the NVP, there is a reported increase in 
the NVP Area under Serum drug Concentration-Time Curve (AUC) with the use of 
depo-medroxy-progestrerone acetate (DMPA) (Pham and Flexner, 2005).  On the 
other hand, ethinyl estradiol‟s AUC is decreased by about 23%, and alternative form 
of contraceptives especially barrier methods are recommended (Pham and Flexner, 
2005).  Efficacy of oral contraceptives may be reduced by the NVP cytochrome P450 
enzyme induction (University of Cape Town 2012).  There is a 35% increase in NVP 
clearance if administered with St. John‟s Wort (Pham and Flexner, 2005). 
 
(v) Drug - food interactions  
No clinically significant interactions documentation was found on nevirapine and food 
(Pham and Flexner, 2005; University of Cape Town 2012). 
 
(vi) Drug - disease interactions  
Hepatitis and many other liver disorders can be complicated by the use of HAART.  
The clinical course of a chronic liver disease is likely to be more aggressive in the 
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presence of HIV infection, than in non HIV infection (Klatt, 2011).  Though it is known 
that HAART improves the clinical course of some liver disorders such as Hepatitis C 
Virus (HCV), some drugs such as nevirapine, and D4T should be used with caution 
as they can aggravate hepatotoxicity (Hoffmann, Rockstroh and Kamps, (ed.) 2007).  
Hepatotoxicity often presenting in the form of hepatitis, hepatic steatosis or hepatic 
necrosis is often associated with most of the classes of HAART medication such as 
NNRTI, NRTIs and PIs (Klatt, 2011; U.S. Department of Health and Human Services 
2005).  
 
People living with HIV are more at risk of developing HAART-related hepatotoxicity if 
co-infected with hepatitis B (Hoffmann, Rockstroh and Kamps, (ed.) 2007).  
Reactivation of hepatitis B has been described following immune reconstitution after 
initiation of HAART (Hoffmann, Rockstroh and Kamps, (ed.) 2007). 
 
Another common syndrome occurring as a result of drug disease interaction is the 
Immune Reconstitution Inflammatory Syndrome (IRIS).   
 
2.3.6. Efavirenz  
(i)  Mechanism of action 
Efavirenz is also a non-nucleoside reverse transcriptase inhibitor and has a similar 
mechanism of action to that of nevirapine described above (Rang et al. 2012).  
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(ii) Pharmacokinetics  
Taking efavirenz with a fatty meal has potential to increase the bioavailability to 
about 50%, protein binding is 99% with the plasma half-life reaching the ranges of 52 
– 76 hours (University of Cape Town 2012).  Efavirenz is metabolised by auto 
induction via the P450 system and is renally and fecally excreted (University of Cape 
Town 2012).  A genetic study presented in Pharmacogenomics. Knowledge. 
Implementation (2012) refers to CYP2B6 as the enzyme with most activity on 
efavirenz.  According to Leung et al (2009), efavirenz is about 90% cleared by the 
CYP2B6 and is metabolized mainly by cytochrome P450 2B6 (CYP2B6) and 
possibly CYP3A4 or other CYP isoforms to a less extent.  It is also an inducer of the 
CYP2B6 and CYP3A4 (Auto-Induction) (Zhu et al. 2009).   
 
(iii) Adverse effects 
Common side effects of this medication are presented with codes in appendix 3. 
 
(iv) Drug - drug interactions  
The interaction between efavirenz and rifampicin has been reported to be minimal 
during clinical trials with some studies recommending an increase in the efavirenz 
dose and others not (MIMS 2010).  In Namibia efavirenz is the selected drug of 
choice for patients on the first line treatment and taking rifampicin (Ministry of Health 
2010), as efavirenz is seen to have lesser interaction with rifampicin.  Caution should 
be exercised for women of child bearing age, as efavirenz may reduce the efficacy of 
oral contraceptives (University of Cape Town 2012).  The St. John‟s Wort is known 
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to induce the metabolism of efavirenz and may lead to its decreased plasma levels 
(University of Cape Town 2012). 
 
(v) Drug - food interactions  
There is a reported increase in the AUC of EFV if taken with fatty meal, with about 
79% increases in serum concentration (Cmax) after a fatty meal, for this reason, 
manufacturers recommend taking EFV on an empty stomach to reduce side effects  
(Pham and Flexner, 2005). 
 
(vi) Drug - disease interactions  
There have been reports of an increase in total cholesterol of about 10 to 20% in 
studies involving non infected volunteers given efavirenz (Drugs online 2012), the 
Namibian guideline on ART (Ministry of Health 2010) requires that clients on 
efavirenz be monitored for fasting cholesterol and triglyceride at 12 months and 
yearly thereafter.  This is because efavirenz has been shown to cause an increase in 
total cholesterol (Maartens et al. 2008).  In anticipation of this interaction, clients with 
pre-existing hyperlipidemia may therefore need to be closely monitored if efavirenz is 
to be used (Drugs online 2012). 
 
Since efavirenz is largely metabolised in the liver, clients with liver disorders are at 
risk from low drug metabolism and drug toxicity, this will call for regular liver function 
monitoring (Drugs online 2012).  Therapy with efavirenz should also be cautiously 
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administered in clients with past and present history of psychiatric disorders and 
discontinuation may be necessary if symptoms worsen (Drugs online 2012). 
 
2.4. Common adverse effects experienced by patients on ARV treatment in 
Namibia 
According to a survey by Ibis Namibia, Lironga Eparu and the Rainbow Project 
(2005), about 57% of clients interviewed had at one point or the other experienced 
adverse effects of which 55% of these clients had reported such side-effects to a 
health care provider.  A similar quantitative research survey done in eight regions of 
Namibia by Van Zyl et al. (2008), highlighted vomiting, headaches, diarrhoea, itching 
and peripheral neuropathy as some of the common adverse effects (AE) reported by 
people living with HIV and AIDS. 
  
Many adverse effects of ARVs are well known and well documented.  They include 
serious and less serious self-limiting adverse effects.  Examples of the serious 
adverse effects of ARVs include pancreatitis, Hypersensitivity reactions, toxic 
epidermal necrolysis, hepatotoxicity, haematological toxicities etc. (Ministry of Health 
2010).  Other classifications include disabling and long term AE such as peripheral 
neuropathy and lipodystrophy respectively (Ministry of Health 2010). 
 
2.5. Opportunistic infections commonly seen in HIV infected patients and their 
treatment 
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Opportunistic infections (OIs) are diseases or infections that do not usually cause 
illness in human, but will usually result in illness when there is a reduction in the 
competency of the immune system (Ministry of Health 2011).  Organisms causing 
opportunistic infections are usually of low or non-virulence in people with intact 
immune systems and may present with an unusual clinical manifestation in 
immunodeficient people (WHO 2009).  This means that the level of immune system 
determines what types of opportunistic infection is likely to be experienced 
(Hoffmann, Rockstroh and Kamps, (ed.) 2007; WHO 2009).  OIs may be regional, 
age or gender associated (Klatt, 2011; Maartens, 2002; WHO 2009).  Tuberculosis is 
the commonest OI associated with morbidity and mortality in Sub-Saharan Africa 
(WHO 2010; Maartens, 2002).  Pneumocystis carinii pneumonia which is the 
commonest opportunistic infection in industrialized countries is uncommon in African 
adults with HIV infection (Maarten, 2002).     
 
Namibia has one of the highest TB burdens in the world.  In 2012, Namibia had a 
case notification rate of 655 per 100 000 population (WHO 2013), with a 45% 
prevalence of HIV among TB patients (Ministry of Health 2013).  Few studies 
highlight the common OIs experienced by HIV positive clients from a Namibian 
context; however the Ministry of Health and Social Services (2010) had listed 
common OIs that are mostly seen in immune reconstitution inflammatory syndromes, 
presented in the table 1 below: 
 
 
 
 
 
- 30 - 
 
Table 1: Opportunistic infection mostly seen in Immune Reconstitution Inflammatory 
Syndromes 
Opportunistic Infection Treatment 
Mycobacterium Avium Complex -Azithromycin,  
Ethambutol, Quinolones or Amikacin 
Cytomegalovirus Valganciclovir and Steroids 
Tuberculosis First line TB treatment include   
Rifampicin, Isoniazid, Pyrazinamide, Streptomycin and 
Ethambutol 
Crypotococcosis Amphotericin B, Fluconazole 
Hepatitis B Virus HAART, to include Lamivudine and Tenofovir 
Herpes Zoster Oral Acyclovir 
Progressive multifocal 
leukoencephalopathy (PML) 
HAART 
 
  Ministry of Health: 2010 
 
 
2.6. Relationships between gender and ARV adverse effects  
Some adverse effects are reported to be more common in a particular gender than 
the other.  For example, the osteopenia and osteoporosis mostly associated with the 
PIs class of medicines are more common in females than their male counterparts 
(US Department of Health and Human Services 2005).  Nevirapine adverse effects 
are likely to be experienced at CD4 counts above 400 cell/ml in male and above 350 
cell/ml in females (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2011; Ministry of Health 2010).  The female sex is also reported to be a risk factor for 
lactic acidosis (Hoffmann, Rockstroh and Kamps, 2007).  A number of adverse 
effects common to female and peculiar to males have been reported and include, 
higher blood levels of ARV medicines due to more fat deposits, abnormal fat 
distribution (lipodystrophy), exaggerated symptoms of osteoporosis etc. (Southern 
Africa HIV and AIDS Information Dissemination Service 2008). 
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2.7. Relationships between ARV adverse effects and treatment regimens 
Different ART regimens are found to present with different types of side effects and 
toxicities.  According to WHO (2008), and Hoffmann, Rockstroh and Kamps, (ed.) 
(2007), mitochondrial toxicity adverse effects are usually associated with NRTI, 
whereas metabolic reactions adverse effects are associated with PIs. On the other 
hand hypersensitivity reactions are mostly associated with NNRTIs.  Although there 
are medicine class specific known adverse effects, most of the adverse effects are 
seen to be drug specifics, such as haematological toxicities associated with AZT and 
renal toxicities associated with tenofovir (WHO 2008). 
2.8. Relationship between adverse effects and duration of treatment 
Adverse effects to antiretroviral medicines have been reported to manifest in 
different trends according to the regimen used.  NRTIs, NNRTIs and PIs are known 
to be associated with earlier gastro-intestinal adverse effects (Hoffmann, Rockstroh 
and Kamps, (ed.) 2007), gastro-intestinal adverse effects occurring later during the 
course of treatment need to be investigated as this could be due to some other 
pathologies (Hoffmann, Rockstroh and Kamps, (ed.) 2007).  Some adverse effects 
are expected earlier while others occur later during the course of treatment (Ministry 
of Health 2010).  Examples include hypersensitivity reaction (HSR) occurring within 
12 weeks of treatment of NNRTI and abacavir HSR that usually occurs in a median 
of eight days (Hoffmann, Rockstroh and Kamps, (ed.) 2007).  Nucleoside reverse 
transcriptase inhibitors related hepatic steatosis is known to be occurring later than 6 
month of treatment (Hoffmann, Rockstroh and Kamps, (ed.) 2007).   
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2.9. Relationship between CD4 count level and ARV adverse effects  
The review had found significant amount of information on studies that looked at the 
relationships between CD4 counts and the types of adverse effects experienced.  A 
prospective study aimed at finding the relationship between CD4 counts and ARV 
toxicities could not yield much information.  In this study, a low CD4 count nadir was 
not associated with higher risks of ARV toxicities (Colette et al. 2005).  On the 
contrary, clients starting nevirapine (NVP) with a higher CD4 count are found to be at 
risk of drug related Hepatitis and pathologic dermatological manifestations (WHO 
2008).  Starting clients with a higher CD4 counts on NVP has shown to be 
associated with more serious toxicities (Panel on Antiretroviral Guidelines for Adults 
and Adolescents 2011; Ministry of Health 2010).  However this seems to be 
challenged in a prospective cohort study by Peters et al. (2010) who concluded that, 
hepatotoxicity and rash after NVP initiation are more related to abnormal baseline 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as opposed 
to higher CD4 counts.  Although this study reported several limitations, other studies 
seemed to have arrived at similar conclusion (Kondo et al. 2008; Knobel et al. 2008).   
 
At times, CD4 count levels may remain low despite a responsive reduction in the 
viral load; this could be associated to neutropenia, an adverse effect of medicines 
such as zidovudine (Hoffmann, Rockstroh and Kamps, (ed.) 2007).  A low CD4 
nadir, has also been identified as a risk factor for lactic acidosis (Hoffmann, 
Rockstroh and Kamps, (ed.) 2007).  Immune Reconstitution Syndrome (IRIS) is 
another adverse effect that is related to the ability of the body to mount an immune 
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response to existing pathologies (WHO 2008).  This condition related to use of ARVs 
is most commonly reported in clients who start ART with CD4 below 50 (WHO 2008). 
2.10. Relationship between viral load and ARV adverse effects 
In a multivariate analysis of a prospective French study involving clients put on 
protease inhibitors, a viral load of 100 000 copies /ml was independently associated 
with severe adverse effects (P= 0.03).  Other independent variables in the same 
study that were associated with severe adverse effects were, creatinine clearance 
below 70ml/min (p=0.007), taking indinavir (p.0.008) and hepatitis B or C infection 
(Carter, 2004).  The preliminary result of the AIDS clinical trial group (ACTG) 5202, 
revealed that there was a difference in the amount and type of adverse effects 
experienced by population starting treatment with viral load below and above 100 
000 copies per ml.  This study was presented at the International AIDS Conference 
in 2008.  In this study, the population starting ARV treatment with viral load above 
100 000 per ml using the regimen that contained abacavir, lamivudine and ritonavir 
boosted atazanavir or efavirenz developed adverse effects 1.89 times faster 
compared to the tenofovir, emtricitabine and efavirenz or ritonavir boosted atazanavir 
regimens.  These results were not ascertained when comparison of the same 
regimens were made in the population starting ARV treatment with viral loads lower 
than 100 000 per ml (Horn, 2008).  There were also differences in the amount of 
adverse effects, where 130 moderate to severe adverse effects were experienced in 
the former regimen group compared to 78 of the later (Horn, 2008).  On the other 
hand, an analysis made by GlaxoSmithKline to challenge the ACTG 5202 results 
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revealed lesser differences and regarded these differences as statistically 
insignificant (Horn, 2008).  The abacavir, lamivudine and ritonavir boosted atazanavir 
or efavirenz regimens in the category of clients starting ARV treatment with pre-
treatment viral loads above 100 000 per ml was later dissolved due to insufficient 
viral suppression.  However the same regimens in the study population starting ART 
with viral loads below 100 000 copies per ml was allowed to continue as this study 
population did not show challenges of increased adverse effects or insufficient viral 
suppression at the study pre-evaluation time.  This may be a representation that, 
higher viral loads are associated with increased adverse effects. 
2.11. Hepatic, renal and hematologic adverse effects of antiretroviral 
treatment 
Alanine transaminase enzyme (ALT) test is not necessarily a liver function test; it is 
mostly used to indicate some degree of liver injury (Haghighat, 2014). In patients 
taking ARVs, hepatotoxicity is always encountered.  Manuela et al. (2012) reported 
that elevated ALT was commonly associated with nevirapine compared to efavirenz.  
According to Manuela, et al. (2012), increases in ALT or and aspartate 
aminotransferase (AST) are common symptoms of hepatotoxicity (Manuela et 
al. (2012).   
 
Serum creatinine levels are often used to determine renal function of patients.  
Although this method provide the much needed information for patient 
management, other test such as the glomerular filtration rates are necessary 
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to recognise renal dysfunction (Duncan et al. 2000).  A study on the creatinine 
levels of patients placed on HAART treatment in South Eastern Nigeria, 
showed elevation in mean creatinine level in 28% of the patients from baseline 
mean range of 1.24mg/dl and 50.71mg/dl to 3.92mg/dl and 71.6mg/dl at 18 
months (Alo, et al. 2012).  This study does however not mention which types 
of antiretroviral combinations were the patients taking.  
Various studies have demonstrated that there are hematologic adverse effects 
associated with antiretroviral medications. A study by Romanelli (2004) 
showed that 77% of the patients who were adherent to zidovudine had 
macrocytosis compared to 18% who were not adherent.  Macrocytosis, 
anaemia, thrombocytopenia were among the commonest haematological 
adverse effects associated with zidovudine in a study by Oshikoya (2012). 
 
2.12. Summary 
Many literatures reveal that patients on ARVs experience more adverse effects 
especially in the initial phases of treatment (Hardon et al. 2006), which tends to 
improves as treatment goes on.  This is related to physiological adaptation (Rang et 
al. 2012).   Literature also still document that patients on ARV treatment will 
experience different adverse effects, manifesting as short term and long term (also 
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called delayed) adverse effects (Ministry of Health 2007; Edward and Aronson, 
2000). 
 
Given the differences in settings in which many of the reviewed studies took place, a 
research from this part of the world does not guarantee similar results.  In 
consideration are facts such as limited resource settings, nutrition, geographical 
location, genetic influences, people‟s habits, existence of co-morbidities, reliance on 
local alternative or traditional medicines, levels of training of the human resource 
managing clients on ARVs, existence of medicine safety regulatory systems etc. 
These independent factors may play a role in the results ascertained in this study.   
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Chapter 3: Materials and methods 
3.1. Study design and site 
This study was done at Keetmanshoop ARV clinic; the researcher used a 
retrospective quantitative study design, in which patients‟ files were used to examine 
follow-up care in the past four years.  Patients who started treatment between the 1st 
of November 2007 and 1st of December 2008 were enrolled into the study.  This 
period was chosen to match the study design, as these patients would have attained 
at least four years of treatment by the time of data collection.  This study period was 
also suitable because it was least affected by changes in the Namibian Ministry of 
health and Social Services ART guidelines (2007) that prescribed for a change in the 
treatment of patients who were placed on stavudine for more than two years.  The 
Namibian Ministry of Health and Social Services ART guidelines (2010) allowed 
patients who were stable on the first line treatment of AZT, 3TC and NVP/ EFV 
based regimens to continue such treatment.  Thus making these patients eligible to 
be included in the study criteria.  Common adverse effects (clinical and laboratory 
findings) experienced at various levels of the first line treatment were looked at.  It is 
presumed that clinicians will order certain tests, or do certain exams related to what 
patients complain of, on this ground the findings of such assessment were reviewed 
for inclusion in the study.  Haematological and biochemical evaluations were done 
using reference ranges set by the country‟s reference laboratory, i.e. the Namibia 
Institute of Pathology (NIP).  Figures outside these set ranges were evaluated and 
considered as adverse effects.  A list of the NIP ranges is attached in Appendix 4.  
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3.2. Inclusion criteria 
The inclusion criteria included all patients male and female, fifteen years and older 
starting the first line ARV treatment or that had stabilised on a first line regimen after 
being changed from earlier treatment regimens that are not part of the study.  
Patients should have attained at least four years (36 – 48 month) of documented 
uninterrupted treatment on the same first line regimen.  The fifteen years age group 
cut off was chosen as it was the age at which children were likely to be placed on 
adult regimens, than the paediatric regimens which starts with stavudine, and would 
be later changed to other regimens (Ministry of Health 2010; Ministry of Health 
2007).  An adverse effect was defined as a deviation (reported, clinical, laboratory or 
biological finding) from the normal findings. 
3.3. Exclusion criteria 
Patients who did not meet the above criteria were not included in the study.  Patients 
whose ART was switched from first to second line ARV treatment were also 
excluded. 
3.4. Sampling and sample size 
According to the electronic dispensing system (Electronic Dispensing Tool), 429 
patients, fifteen years and older were started on treatment between the 1st 
November 2007 and 1st December 2008.  Of this number, 294 patient records were 
found. The ascertained patient records were numbered and a random number 
generator using Stata 12.1 was done to select the records to be included in the 
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study.  The Taro Yamane simplified formula was utilized to calculate the sample 
sizes for proportions as follows (Israel, 2008):  
n = 
²)(1 eN
N

     
Sample sizes was calculated for +/- 5% precision levels where confidence intervals 
is 95% and a maximum variability (P = .5). 
N = Population size 
n = Sample size 
e = required size of standard error 
Size of population 
(N) 
Sample Size (n) for Precision (e) of: 
±5% ±7% ±10% 
100 80 57 36 
125 95 65 39 
150 109 71 42 
175 122 76 43 
200 133 81 45 
225 144 84 46 
250 154 88 47 
275 163 91 48 
294 169 93 48 
325 179 95 49 
 
3.5. Data collections 
Data collection was done from 21st December 2012 to the 4th January 2013. Two 
nursing staff were trained on data collection and assisted with the data collection 
under guidance of the researcher.  Patient files were used to generate data which 
was entered into the data collection tool.  Any other significant adverse effects were 
entered into the data collection tool.  Entry into the data collection tool (Appendix 5) 
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was according to months the treatment was started.  For example, month one, is the 
month when the patient was started or transitioned to the first line treatment under 
the study. 
3.6. Classification and ranking of adverse effects 
Classification of adverse effects was done using the Naranjo adverse drug reaction 
probability scale (Doherty, 2009).  Although the Naranjo scale is more applicable 
when assessment are done in a controlled environment such as a situation where re-
challenge of the suspected medication is achievable, assessment of the adverse 
effects ascertained in this study fell in the possible Adverse Drug Reaction (ADR) 
category.  Consequently a definition of adverse effects instead of ADR was used in 
the study.  
3.7. Parameters assessed 
The following parameters were assessed and used in various statistical tests:   
 3.7.1. Demographic characteristics 
The demographic characters that were assessed are gender and age.   
3.7.2. Pharmacotherapeutic characteristics 
The pharmacotherapeutic characters that were assessed are regimen types and 
duration of treatment.  Assessment was also done on the implications of earlier 
exposure to ART compared to no exposure. 
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3.7.3. Hematologic and Immunologic profile 
Hematologic and immunologic profile assessed included haemoglobin levels, red cell 
counts, mean cell haemoglobin, CD4 counts and white cell counts etc.       
3.7.4. Biochemical characteristics 
Biochemical parameters assessed the liver and renal function status by looking at 
the alanine transaminase enzymes and creatinine levels, abnormality of which was 
classified as adverse effects.  
3.7.5. Data analysis  
Data was analysed using Stata 12.1., an American statistical software package 
produced by StataCorp based in College Station, Texas. (StataCorp. 2011. Stata 
Statistical Software: Release 12. College Station, TX: StataCorp LP).  Using this 
software various statistical tests were used.   
3.7.6. Ethics approval 
 
The information obtained was handled with strict confidentiality, with no use of 
patient names for anonymity purposes.  The study was approved by the ethics 
committee of the University of the Western Cape (Ethics certificate number: 12/6/45) 
and the Namibian Ministry of Health and Social Services (see appendixes 1and 2).  
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3.8. Limitations 
The major limitation of this study was the low numbers of patients that resulted in 
wider confidence intervals.  Other parameters could not be assessed due to low 
numbers, e.g. patients who had viral load results were few. 
 
Results are based on the recorded information from health workers, whereas it is 
mandatory for health workers attending to the patient to record findings from patient 
assessments, it is also common knowledge that variation in what health workers will 
consider as important information to be recorded can occur.  Thus, the result of a 
retrospective record based study is limited to existing data and is as good as the 
quality of the recordkeeping. Furthermore, this study also suffers from weakness of 
retrospective studies in determining causation i.e. some other factors such as 
alcohol or lifestyle or none recorded medications taken by the studied patients could 
have contributed to the abnormal findings.  Abnormal findings could also relate to the 
disease process or any pathologies and not necessarily to the medications.  
However there are agreements between this study and many other studies that point 
to consistencies in the results.  
 
Cotrimoxazole was recorded to have been used in 91% of the patients; this means 
some adverse effects ascertained in the study could also relate to it.   
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Chapter 4: Results 
4.1. Introduction 
The study aimed at finding common adverse effects experienced by HIV-positive 
patients treated with first line ARV treatment at Keetmanshoop ART Clinic.  The 
study also aimed at assessing the risk factors for development of adverse effects in 
HIV-positive patients on antiretroviral therapy (ART).  Specific objectives of the study 
were to determine if there is any association between adverse effects (clinical and 
laboratory findings) and any of the following factors: patient gender, drugs used, 
treatment duration, patient age and stage of HIV infection.  This chapter present the 
various findings of the study.  The results are presented starting with the background 
of the patients and later results of the various statistical tests performed.  
  
4.2. Demographics characteristics  
The gender and age distribution of the 94 studied patients is presented in table 2 
below.  The median age was 38, with age ranges of 18 to 69.   
 
Table 2: Demographic characteristics of the studied patients 
Demographic Factor Number Percent 
Gender distribution   
     Male 33 35 
     Female 61 65 
Age distribution   
     18 – 24 4 4.3 
     25 – 34  30 31.9 
     35 – 44 31 32.9 
     45 – 69 29 30.9 
   
 
 
 
 
- 44 - 
 
4.3. Therapeutic and clinical profile 
Table 3 below shows the therapeutic and clinical profiles of the 94 studied patients.  
Among a total of 94 studied patients, 54% remained on the first line ARV treatment 
(herein classified as first treatment) under study for a period up 36 to 48 month, while 
46% of the patients were transitioned (herein referred to as transitioned) from a 
different regimen and stabilised on one of the first line alternative treatment for the 
duration of the studied period.  For a list of the first line drugs see section 2.3.1.  
Only 6% of the 94 patients were found with records of being on chronic medications 
other than ARVs, they included five patients on amiloride hydrochloride, and one 
patient on an unmentioned anti-asthmatic medication. 
 
As a measure of liver function abnormality as an adverse effect, about 40% of the 
studied patients had one or more elevated ALT test results during the duration of the 
treatment.  This was measured by aggregating into one group, the patients who 
experienced one or more elevations in the measured ALT tests throughout the study 
period, compared to the group of patients that never experienced any elevation in 
the measured ALT tests during the study period.  Using this same principle in 
measuring the renal function of the studied patients, 59% of the patients experienced 
an elevation in their creatinine test result.  
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4.4. Prevalence of patient reported adverse effects  
Only 44 out of 94 (46%) patients had reported an adverse effect during their visits to 
the ARV clinic in the period of 36 – 48 months.  Of these patients, 31 were females 
and 13 were males.  Out of the 44 patients, 33 were on the NVP based regimen and 
11 were on efavirenz.  The statistical significant relationship between prevalence of 
patient reported adverse effects and type of regimen and CD4 count were tested 
using the Pearson chi square test.  CD4 count medians achieved at 36 – 48 month 
of treatment were calculated for each patient and categorized into CD4 count of 1 – 
300 and 301 and above.  There were no statistically significant associations between 
the regimen base patients were on and the reported adverse effects.  There was 
also no statistically significant association between the reported adverse effects and 
patient CD4 counts.  Table 4 below shows the five most reported adverse effects, 
Table 3: Therapeutic and Clinical profile of the studied patients 
Therapeutic/Clinical Factor Number Percent 
Regimen base   
     AZT/3TC/NVP 72 77 
     AZT/3TC/EFV 22 23 
Treatment status   
     First treatment 51 54 
     Transitioned  43 46 
Cotrimoxazole use   
     Recorded 86 91 
     No record 8 6 
Median CD4 Counts   
0 - 300 36 38 
> 301  58 62 
Average high ALT    
None 56 60 
Positive 38 40 
Average high creatinine   
none 16 41 
Positive 23 59 
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percentages calculated from the numbers of patients with recorded adverse effects 
and the p-values of the Pearson chi-square test used to test for associations.  
 
Table 4: Commonly reported adverse effects by patients on first line ART 
treatment  
 
Complaints Number of patients 
reporting the adverse 
effect at any period 
% Association 
with regimen 
 P-value: 
Association 
with CD4 
 P-value: 
1. Musculoskeletal Disorder 11 25 0.747 0.467 
2. Skin disorder 9 20 0.459 0.799 
3. Cough 9 20 0.930 0.088 
4. Gastro intestinal disorders 8 18 0.446 0.122 
5. Headache 7 16 0.750 0.607 
 
 
4.5. Prevalence of haematological, renal and liver function adverse effects in 
the studied patients  
All 94 patients were assessed for haematological, renal and liver function related 
adverse effects using the recorded blood results.  The Namibian Institute for 
Pathology (NIP)‟s reference ranges were used to classify the disorders from the 
norm.  The disorders were then classified as adverse effects and were taken from 
any stage of treatment period per patient i.e. patients who would have had an 
abnormality in the haematological profile at any stage would be classified as positive 
for that particular hematologic test at the end of the assessment period of 36 – 48 
months.  The common haematological, renal and liver function related adverse 
effects as ascertained from the full blood counts  are illustrated in figure 3 below.  
The most common haematological adverse effect ascertained was the low HB, 
followed by higher mean cell haemoglobin (MCH).  The least common adverse effect 
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was the low Mean Platelet Volume (MPV) and low Red cell Distribution Width 
(RDW). 
Figure 1: Common haematological, renal and hepatic adverse effects ascertained  
 
Key: H=High, L=Low 
 
4.6. Association between haematological, renal and liver function adverse 
effects and the gender of the studied patients 
To understand if some haematological or renal and liver function adverse effects 
were more common in male or female patients, a Pearson chi square test was 
performed to test for statistical significance in selected prominent adverse effects.  A 
 
 
 
 
- 48 - 
 
null hypothesis of no association was assumed.  Figure 5 depicts the point 
prevalence and confidence intervals of selected adverse effects.  
Figure 2: Common haematological and renal adverse effects among adult male and female patients 
showing point estimates and 95% confidence intervals 
 
 
4.6.1. Association between gender and low hemoglobin levels 
All 94 patients had a haemoglobin (HB) test done at most times during their follow up 
visit to the ART clinic, 61 were females and 33 were males.  More male patients 
(88%, 95%CI: 76.4 – 99.3) experienced low haemoglobin compared to female 
patients (69%, 95%CI: 56.9 – 80.7).  This difference was statistically significant 
(p<0.04) and rejects the null hypothesis of no association.  
 
The low haemoglobin was further divided into three categories, i.e. patients who had 
no low HB, patients who had low HB in 1 to 49% of the tests done, and patients who 
had low HB in 50% and more of the tests performed.  This was done to try and 
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classify low HB as an adverse effect if it persisted for up to 50% or more of the tests 
done.  As highlighted in figure 3, more males than female patients were still found to 
have low HB persisting in 50% and more of the total tests taken, 55% (95%CI: 37.0 – 
72.0) and 25% (95%CI: 13.5 – 35.6) respectively (p=0.004).  When adjusted for 
regimen type, a male patient was three times likely to have a low haemoglobin level 
compared to a female patient (OR: 3.29, 95% CI: 1.3 – 8.3). 
Figure 3: Changes in haemoglobin levels in relation to gender  
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4.6.2. Association between gender and high mean haemoglobin (MCH) levels 
Another statistically significant test was the association between gender and high 
MCH.   Only 77 out the 94 patients were found to have ever had an MCH test.  Of 
the tested patients, there were 49 females and 28 male patients.  More of the female 
patients (73%, 95%CI: 60.7 – 86.1) were found to have ever recorded an elevated 
MCH compared to male patients (50%, 95%CI: 30.8 – 69.1).  This difference was 
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statistically significant (p<0.05) (OR: 0.36, 95%CI: 0.13 – 0.95%).  With adjustment 
for regimen, a male patient was still found to be 69% times (0.31 – 1 X 100 = 69%) 
less likely to have a higher MCH result compared to a female patient (OR. 0.31, 95% 
CI: 0.11 – 0.87). 
4.6.3. Association between gender and other various hematological, renal and liver function 
adverse effects of the studied patients 
No statistically significant differences were ascertained when a Pearson chi square 
and a Fischer‟s exact test were performed on the association between genders and 
further haematological, renal and liver function related adverse effects.  These 
results are depicted in table 5 below.  
Table 5: Statistical significance testing results between male and female patients and various 
haematological, renal and liver function adverse effects 
 
Hematologic 
Disorder 
SEX Ever 
experienced an 
abnormality  
Patient 
Denominator 
(Total number 
of patients) 
Statistical 
significance 
Low Red Cell Count 
(RCC) 
Females 36 (71%) 51 None 
(P=0.092) Males 15 (52%) 29 
High Mean Cell 
Volume (MCV) 
Females 37 (76%) 49 None 
(P=0.073) Males 15 (56%) 27 
Low Hematocrit Females 27 (54%) 50 None 
(P=0.896) Males 15 (56%) 27 
High Creatinine Females 15 (60%) 25 None 
(P=0.715) Males 7 (54%) 13 
High Alanine 
transaminase (ALT) 
Females 21 (34%) 61 None 
(P=0.107) Males 17 (52%) 33 
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4.7. Association between haematological, renal and liver function adverse 
effects and drug groups 
Patient‟s parameters were assessed to demonstrate differences in the common 
haematological, renal and liver function adverse effects experienced between 
nevirapine and efavirenz based treatment groups.  The denominators was not the 
same for all haematological and biochemical tests performed.  There were 22 
patients on efavirenz and 72 on nevirapine based regimen.   
 
The most prominent results as presented in figure 4 were selected to test for 
statistical significance of association between nevirapine and efavirenz based 
treatment groups using Pearson chi square test.  The null hypothesis of no 
association was assumed.  
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Figure 4: Association between NVP and EFV based treatment and the haematological, renal and 
hepatic adverse effects 
 
 
4.7.1. Association between treatment regimen and renal adverse effects by measure of 
creatinine level  
To assess the renal function related adverse effects of the studied patients, an 
association between high creatinine levels and regimen status was tested using the 
Pearson chi square exact test and the result showed that there was a statistically 
significant association between the regimen base patients were on and an elevated 
creatinine levels (p<0.003).  More patients on nevirapine base (70%, 95%CI: 54.1 – 
87.7) experienced elevated creatinine levels compared to efavirenz base (12%, 
95%CI: 12.0 – 37.8).  A patient on nevirapine was more likely to experience an 
elevated creatinine level compared to a patient on efavirenz (OR 36.0, 95% 2.02 – 
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62:  adjusted for gender, age and CD4 count median), this was statistically 
significant at p=0.0027.  This finding rejects the null hypothesis of no association and 
suggests that a patient on nevirapine base was more likely to experience elevated 
creatinine levels than a patient on efavirenz. 
4.7.2. Association between treatment regimen and other hematological and liver function 
adverse effects 
There was no statistically significant association between regimen base and various 
haematological and liver function adverse effects, low haemoglobin (p= 0.191), high 
ALT (p= 0.347), high MCV (p= 0.254), high MCH (p = 0.714), low red cell count (p= 
0.502) and low Hematocrit (p= 0.162). 
4.8. Association between duration of treatment and haematological, renal and 
liver function adverse effects of the studied patients 
This section looks at the haematological, renal and liver function adverse effects in 
two groups of patients. The first group of patients were started on the first line 
treatment and were kept on this line for a period of 36 to 48 months, herein referred 
to as “first treatment”. The second group are patients who had some exposure to 
ART treatment and were transitioned and stabilised on the first line treatment under 
the study for a period of 36 to 48 month, herein referred to as “transitioned”.  A 
Pearson chi square test was performed to test for statistical significant associations 
between haematological, renal and liver function adverse effects of the two groups.  
Two points were compared, i.e. the frequency of a particular adverse effect at 
treatment initiation (baseline) and the overall frequency if a patient have ever 
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recorded a particular adverse effect at any time during the treatment period which 
was evaluated at 36 to 48 month of treatment.  The baseline period for the patients 
who were transitioned was the tests performed when they were being transitioned to 
the standard first line treatment under study.  This information is summarised in table 
6 below.     
Table 6: Association between treatment status and commonly experienced haematological, renal and 
liver function adverse effects at baseline and at 36 to 48 month evaluation   
 
Hematologic Disorder Treatment 
Status 
Patients 
with 
Baseline 
abnormal 
Results 
Statistical 
significan
ce 
Ever 
experienced 
an adverse 
effect  
Statistical 
significance 
Low hemoglobin First 
treatment  
32 (80%) Yes 
(P=0.003) 
43 (84%) Yes 
(P=0.031) 
Transitioned 12 (44%) 28 (65%) 
High Mean Cell Hemoglobin First 
treatment 
6 (17%) Yes, 
(P=0.000) 
21 (50%) Yes, 
(P=0.003) 
Transitioned 17 (68%) 29 (83%) 
Low Red Cell Count (RCC) First 
treatment 
13 (37%) Yes, 
(P=0.040) 
25 (58%) No, 
(P=0.260) 
Transitioned 16 (64%) 26 (70%) 
High Mean Cell Volume (MCV) First 
treatment  
6 (17%) Yes, 
(P=0.000) 
23 (56%) Yes, 
(P=0.012) 
Transitioned 17 (68%) 29 (83%) 
Low Hematocrit First 
treatment 
24 (69%) Yes, 
(P=0.012) 
27 (64%) No, 
(P=0.060) 
Transitioned 9 (36%) 15 (43%) 
High creatinine First 
treatment  
2 (50%) No, 
(P=0.361) 
11 (52%) No, 
(P=0.444) 
Transitioned 0 (0%) 11 (65%) 
High Alanine transaminase 
(ALT) 
First 
treatment  
4 (10%) No, 
(P=0.164) 
22 (43%) No, 
(P=0.560) 
Transitioned 7 (21%) 16 (37%) 
 
 
The most common type of haematological adverse effects in the first treatment group 
at baseline was low haemoglobin (80%); low hematocrit (69%) and low red cell count 
(37%).  This differed with the treatment exposed (transitioned) group in which the 
 
 
 
 
- 55 - 
 
most common haematological adverse effect at baseline was the high mean cell 
volume and high mean cell haemoglobin of 68% respectively.  This is followed by 
low red cell count (64%), low haemoglobin (44%) and low Hematocrit (36%).    
 
At baseline, a patient who was exposed to prior ART treatment had a 67% reduced 
risk of having lower haemoglobin level, compared to a patient who had no prior ART 
exposure (RR: 0.33, 95%CI: 0.37 - 0.81).  However this risk was reduced to 23% 
when the two groups were evaluated at 36 – 48 month of treatment (RR: 0.77, 95CI: 
0.60 – 0.97). 
On the contrary, at baseline, a patient who had prior exposure to ART had a three 
times increased relative risk of experiencing a high mean cell haemoglobin (MCH) 
compared to a patient with no ART exposure (RR: 3.6, 95%CI: 1.91 – 7.14).  
However, at 36 – 48 month of treatment, this risk reduced to 1.65 (RR, 95%CI: 1.18 
– 2.30) between the two groups.  
 
After adjustment for gender, regimen, CD4 count and age, at baseline, a patient who 
had prior exposure to ART (transitioned group) had 81 times (adjusted OR: 81.4, 
95%CI: 5.3 – 119, p-value=0.00) increased odds of experiencing a high mean cell 
volume (MCV) compared to a patient with no ART exposure (first treatment).    
However at 36 – 48 month of treatment, with the same adjustment, this risk has 
reduced to 2.89 times (95%CI: 0.87 – 9.07, p-value=0.08). 
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At baseline, a patient who had prior exposure to ART was found to have a three 
times increased odds of experiencing a low red cell count compared to a none ART 
exposed patient (unadjusted OR: 3.0, 95%CI: 1.03 – 8.73).  However at 36 – 48 
month of treatment evaluation, the findings were not statistically significant at p-value 
of 0.262 (unadjusted OR: 1.70, 95%CI: 0.67 – 4.31). 
4.9. Association between age and various hematological, renal and liver 
function adverse effects of the studied patients 
Correlation between age and the various haematological adverse effects was not 
possible as it was difficult to use parametric tests due to the skewness of the data 
distribution.  To assess for association between age and various haematological 
adverse effects, the age categories were disaggregated into the ages of 18 – 24, 25 
– 34, 35 – 44, and 45 – 70.  The patient‟s categorical ages were then used to test for 
association between age groups and various adverse effects using the Pearson chi 
square test.  There were no statistically significant associations between age and 
any hematologic, renal and liver function adverse effects.  The results showing the p-
values are summarised in table 7 below.  
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Table 7: Association between patient age and selected common haematological, renal and liver 
function related adverse effects using Pearson chi square test   
 
 
Hematologic Adverse effects  
 
Statistical significance 
 
CD4 count median No, (P=0.869) 
Low Haemoglobin No (P=0.376) 
High Mean Cell Hemoglobin No (P=0.296) 
High Mean Cell Volume (MCV) No, (P=0.518) 
High creatinine No, (P=0.576) 
High Alanine transaminase (ALT) No, (P=0.721) 
 
 
 
4.10. Association between CD4 count and haematological, renal and liver 
function adverse effects of the studied patients  
To answer the question of whether there were associations between CD4 counts 
and the various hematological, renal and liver function adverse effects of the studied 
patients, CD4 count medians achieved at 36 – 48 month of treatment were 
calculated for each patient and categorized into CD4 count of 1 – 300 and 301 and 
above.  Various hematologic, renal and liver function related adverse effects were 
then also stratified into never recorded an adverse effect and ever recorded an 
adverse effect at 36 – 48 month evaluation.  This was done for all tests results 
shown in table 8 in exceptions of the lower hemoglobin and high ALT variable.  The 
lower hemoglobin and high ALT variables were stratified into patients who 
experienced low hemoglobin and high ALT in 1 – 49% percent of the tests done 
during the treatment period, and those who experienced low hemoglobin and ALT in 
50% and above of the tests done during the treatment period.  This was done 
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because lower hemoglobin and high ALT test results were recorded more frequently 
than other tests, and therefore warranted better classification.   A Pearson chi square 
test was then performed to determine if there were any associations between CD4 
count categories and various hematologic, renal and liver function adverse effects.  
Results of these tests are show in table 8 below.  
Table 8: Association between CD4 count and selected common haematological, renal and liver 
function adverse effects using Pearson chi square test 
Hematologic 
Disorder 
CD4 
count 
Ever 
experienced an 
abnormality  
Patient 
Denominator 
(Total number 
of patients) 
Statistical 
significance 
Low hemoglobin 1 – 300  19 (53%) 36 Yes  
(P<0.05) ≥ 301 14 (24%) 58 
High Alanine 
transaminase (ALT) 
1 – 300  19 (53%) 36 Yes (marginal) 
(P=0.055) ≥ 301 19 (33%) 58 
High Mean Cell 
Volume (MCV) 
1 – 300  20 (69%) 29 None 
(P=0.936) ≥ 301 32 (68%) 47 
Low hematocrit 1 – 300  19 (66%) 29 None 
(P=0.133) ≥ 301 23 (48%) 48 
High creatinine 1 – 300  10 (71%) 14 None 
(P=0.197) ≥ 301 12 (50%) 24 
Low Red Cell Count 1 – 300  17 (55%) 31 None  
(P=0.187) ≥ 301 34 (69%) 49 
 
As can be seen from the table above, patients with higher CD4 counts were less 
likely to experience low hemoglobin levels compared to patients with low CD4 counts 
(24%, 95%CI: 12 - 35 vs. 53%, 95%CI: 36 - 69) (p<0.05), When adjusted for regimen 
type and treatment status the OR was 0.31 (95%CI: 0.12 – 0.77).  Patients with 
higher CD4 counts were also less likely to experience elevated ALT enzyme levels 
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compared to patients with low CD4 count (33%, 95%CI: 20 - 45 vs. 53%, 95%CI: 36 
- 69) (p= 0.055).  The unadjusted OR was 0.22 (95%CI: 0.06 – 0.78). After 
adjustment for treatment status and regimen type, the OR was 0.20 (95%CI: 0.05 – 
0.76).  
Figure 5:  Association between median CD4 counts and low hemoglobin level and high ALT  
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Chapter 5: Discussion  
5.1. Prevalence of adverse effects  
Out of the 94 eligible patients records assessed, only 44 patients were found to have 
reported an adverse effect.  Much could not be deduced from these findings due to 
low numbers of ascertained records with reported adverse effects.  This made 
further analysis and test for association to be inconclusive; hence no further 
stratification is reported.  The low number of reported adverse effects could indicate 
the need for improved recordkeeping.  It may also indicate the less attendance of 
patients to the ARV clinic when experiencing a complaint, i.e. patients may at the 
time when experiencing adverse effects use other health facilities.  Lesser 
information is available to classify musculoskeletal disorder ascertained as a 
commonly reported adverse effect among patients in this study. Musculoskeletal 
adverse effect was a culmination of various musculoskeletal adverse effects 
reported; therefore there is a likelihood that this finding may related to advanced age, 
chance finding or other pathologies in the studied patients.  The lack of association 
between reported adverse effects, CD4 counts and regimen could also suggest a 
weak association or inconsistencies in reporting or recording of adverse effects.  
Despite these limitations, our study agrees with the study by Van Zyl et al. (2008), 
which concluded that the common adverse effects affecting patients on ART 
included headaches, nausea, diarrhoea, itching etc. 
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5.2. Prevalence of haematological, renal and liver function adverse effects in 
the studied patients 
The most common haematological adverse effect ascertained was a low HB, 
followed by higher mean cell haemoglobin (MCH), higher mean cell volume (MCV) 
and low red cell counts.  This finding agrees with many other studies that highlighted 
low haemoglobin to be the most common blood disorder in HIV infected patients 
(Friel and Scadden 2011).  Owiredu et al. (2011) highlighted the prevalence of lower 
haemoglobin in HAART naive HIV positive patients to be 70%, which is consistent 
with 80% ascertained in this study.  Causes of anaemia in HIV infected patients are 
varied and may range from changes in cytokine production with subsequent effects 
on hematopoiesis, opportunistic infections, chemotherapeutic agents such as 
zidovudine and trimethoprim-sulfamethoxazole, cancers, autoimmune destruction of 
red blood cells etc. (Sullivan et al. 1998).   
5.3. Association between haematological, renal and liver function adverse 
effects and the gender of the studied patients 
Our study ascertained that anaemia was more prevalent in males than females 
patients, (adjusted OR: 3.29, 95% CI: 1.3 – 8.3) (p< 0.04).  A study by Omoregie et 
al. (2009), reported a higher prevalence of anaemia in HAART naive HIV positive 
male patients than female patients (76% vs. 63%), however this study did not report 
a statistically significant differences in anaemia between the two sexes when 
patients were on HAART.  Many factors may account for statistical difference in low 
haemoglobin between male and female patients on ART, as ascertained by this 
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study.  Among others are possibilities that adherence to treatment between male and 
female patient is different.  An extreme classification of abnormal haemoglobin levels 
by the reference laboratory which may not be reflective of the community averages is 
another hypothesis.  These areas may need to be investigated further.  A finding in 
contrast to our study, of HIV negative Ugandan by Lugada et al, (2004) highlighted 
that after age 13, males were more likely to have higher haemoglobin levels 
compared to females.  This finding agrees with a cross sectional study by Messanh 
et al, (2011) that assessed haematological reference values in health individuals in 
Togo.  The study ascertained that male health individuals generally had higher 
haemoglobin and higher MCH compared to female individuals (Messanh et al. 2011).  
 
In the presence of HIV and ART, causes of anaemia are varied and could be both 
due to disease process and use of ARVs and other chemotherapeutic agents 
(Sullivan et al. 1998).  In our study more female patients were found to have 
experienced higher MCH than male patients 73% (95%CI: 60.7 – 86.1) and 50% 
(95%CI: 30.8 – 69.1) respectively.  The MCH test is said to be identical with the MCV 
test in providing information related to the diagnosis of anaemia (WHO 2004).  An 
elevated MCH is always associated with macrocytic anaemia which is common in 
people using zidovudine and related medications among other possible causes 
(Claster, 2002).  It is difficult to speculate the cause of the statistical difference in 
MCH between males and female patients with lesser available literature.  One theory 
could be that the difference in MCH between males and female patients could point 
to the differences in adherence levels.  A study by Mugisha et al. (2012) reported an 
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elevated MCV levels to be a possible marker for adherence and response to AZT 
containing therapy.  According to the Southern Africa HIV and AIDS Information 
Dissemination Service (2008), Numbers of adverse effects common to female and 
peculiar to males have been reported and include, higher blood levels of ARV 
medicines due to more fat deposits, abnormal fat distribution (lipodystrophy) and 
exaggerated symptoms.  Our study agrees with studies that highlighted that HIV-
infected male patients had increased risks of having anaemia than female patients 
(Omoregie et al. 2009).  
5.4. Association between haematological, renal and liver function adverse 
effects and drug groups 
There was no association between regimen type and these haematological and liver 
function adverse effects; HB (p=0.177), ALT (p=0.347) and MCV (p= 0.254).  
However more patients on nevirapine base (70%) experienced elevated creatinine 
levels compared to efavirenz base (12%), (p<0.003).  This finding suggests 
increased risk of renal adverse effects for patients on nevirapine.  However there 
might be a need to study this risk with a stronger sample size.    
 
This finding is closely supported by findings of a prospective study by Namu (2013) 
which ascertained an increase in creatinine levels associated with the use of ARVs 
(mean increase of 1.03mg/dl at baseline to 1.37mg/dl at 6month).  ARVs in this 
setting were zidovudine, stavudine and nevirapine.  A study on the creatinine 
levels of patients placed on HAART treatment in South Eastern Nigeria, 
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showed elevation in mean creatinine level in 28% of the patients from baseline 
mean range of 1.24mg/dl and 50.71mg/dl to 3.92mg/dl and 71.6mg/dl at 18 
months (Alo, et al. 2012). Namu et al. (2013), also cited a study by Hirsch and 
Gunthad, (2005) which did not find a significant increase in creatinine levels in 
patients who were taking cotrimoxazole.  This lessens the possibility of the elevated 
creatinine levels to be associated with the use of cotrimoxazole, which is a common 
medication found to have been used in 91% of the patients under this study.  An on-
going online study by eHealthMe (2013) based on reports from patients taking 
nevirapine revealed a 0.77% (40 out of 5 171) prevalence of elevated creatinine.   
 
Although there is limitations related to low numbers of patients used in our study, the 
eHealth (2013) study also have limitation relating to lack of control in the 
environment.  
 
 These finding raises interest to which the author recommends further controlled 
studies that will compare the nevirapine and efavirenz regimens and creatinine 
elevation.  
5.5. Association between duration of treatment and haematological, renal and 
liver function adverse effects of the studied patients 
An ART exposed patient was less likely to experience a low haemoglobin than an 
ART naïve patients, (1.65, RR: 95%CI: 1.18 – 2.30) (p<0.003).  This finding 
suggests that there is an improvement in patient‟s health status related to the use of 
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ARVs and agrees with a study by Owirendu et al (2011) who reported a higher 
prevalence of anaemia in HAART naïve patients compared to patient on HAART.    
 
At baseline ART naïve patients were also less likely to experience  elevated mean 
cell volume (MCV) and MCH than ART exposed patients, 17% versus 68%, 
(p<0.00).  At 36 – 48 month evaluation after being on treatment, the category of 
patients who were earlier exposed to ART had experienced elevated MCV more 
times than the patients who were ART naïve at baseline, 83% versus 56% p-
value=0.012.  This finding suggests a cumulative and more macrocytic picture 
occurring as treatment advances and may be suggestive of bone marrow depression 
related to the use of AZT and Cotrimoxazole.  Hypothetically, anaemia experienced 
in the initial phases could relate to iron deficiency, anaemia of the chronic disease or 
vitamins and nutrients deficiency.  Anaemia occurring during the later period of 
treatment points to a more macrocytic cause, which can relate to the use of AZT, 
cotrimoxazole and bone marrow suppression.  This hypothesis is also highlighted 
and supported by Owiredu (2011).  Further studies aimed at understanding the 
cause and implications of this scenario are recommended. 
 
5.6. Association between CD4 count and haematological, renal and liver 
function related adverse effects of the studied patients 
This study ascertained that there is an association between CD4 count and low 
haemoglobin. Patients with higher CD4 counts had reduced chances of experiencing 
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lower haemoglobin levels compared to patient with lower CD4 counts. This supports 
other findings highlighted earlier that, treatment with ART, which is always related to 
improved CD4 counts reduces the likelihood of having anaemia and abnormal liver 
enzymes.   Our study agrees with findings of a study by Meidani et al. (2012), that 
ascertained that Anaemia was more prevalent in patients with lower CD4 counts 
(CD4 count of <100, (77%), 100 – 249, (83%) >250 (54%)).   
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Chapter 6: Conclusions and Recommendations 
6.1. Conclusions 
This document presented findings of a retrospective study done to ascertain the 
adverse effects experienced by patients on first line antiretroviral treatment at 
Keetmanshoop Hospital.  Adverse effects associated with antiretroviral treatment 
were looked at in terms of clinical, immunologic, hematologic and biochemical 
changes (renal and liver function).   
 
The most commonly reported adverse effect was musculoskeletal disorders (25%), 
followed by skin disorders and cough at 20% respectively.  The most common 
haematological adverse effects were lower haemoglobin, high mean cell 
haemoglobin and lower red cell count.  Male patients had higher prevalence of low 
haemoglobin compared to female patients.  Patient on nevirapine based NNRTI had 
about five times increased risk of elevated creatinine level compared to patients on 
efavirenz. Elevated mean cell haemoglobin was more common in later treatment 
periods than initial treatment periods. Lower haemoglobin and elevated ALT were 
less common in patients with Higher CD4 count compared to patients with lower 
CD4 count.     
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6.2. Recommendations  
Low numbers of patients with recorded adverse effects led to inconclusive results on 
what is the most common adverse effect raised by patients on ART, clinicians may 
need to inquire more and record the client‟s complaints.  Conducting a prospective or 
a random controlled study with higher sample size may yield better result in this 
area.  
 
Factors that may results in a statistical difference in Anaemia between male and 
female patients on ART can also be explored.   
 
Creatinine was found to be higher in patients on the nevirapine based regimen 
compared to patients on the efavirenz base.  The author recommends further studies 
with higher sample size to confirm whether higher creatinine levels were more in 
patients on nevirapine compared to efavirenz; this will have clinical implications 
especially in patients with impaired renal system.   
 
Antiretroviral treatment increases chances of developing macrocytosis, clinical 
implication of this condition is unknown and will need to be investigated.  
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Appendix 3: Codes for adverse effects 
First line Regimens; 
 
Tenofovir (TDF), Lamivudine (3TC) and Nevirapine (NVP) 
 
First line alternatives 
Tenofovir (TDF), Lamivudine (3TC) and Efavirenz (EFV) 
AZT, 3TC and NVP 
AZT, 3TC and Efavirenz (EFV) 
 
Known or expected adverse effects of first line antiretroviral medications (ARVs) (Division of 
Pharmacology, Faculty of Health Science, University of Cape Town. 2005). 
 
Zidovudine (AZT) adverse effects  
 
A1.   Anemia 
A2.  Leucopenia 
A3.  Neutropenia 
A4.  Myalgia 
A5.  Insomnia 
A6.  Myopathy 
A7.  Seizures 
A8.  Confusion 
A9.  Mania 
A10.  Hepatotoxicity 
A11.   Acidosis  
A12.   Depression 
 
Lamivudine (3TC) adverse effects (Infrequent) 
 
 L1.  Pancreatitis 
 L2.  Diarrhoea 
 L3.  Malaise 
 L4.  Upper Abdominal Pain 
 L5.  Alopecia 
 L6.  Parasthesia 
 
Tenofovir adverse effects 
 T1. Mild to moderate gastro-intestinal disturbances 
 T2. Nephrotoxicity 
 T3.  Rarely: hypersensitivity reaction, hyperlactaemia and hepatic steatosis 
 
Nevirapine (NVP) adverse effects 
 
 N1. Clinical Hepatitis 
 N2. Granulocytopenia 
 N3. Gastrointestinal Intolerance 
 
Adverse effects shared by AZT, 3TC and NVP 
 ALN1.  Peripheral Neuropathy 
 ALN2.  Nausea and Vomiting 
 ALN3.  Headaches 
 AL4.   Hyperlactaemia 
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 AL5.   Hepatic Steatosis 
 LN6.   Rash 
 LN7.  Fever 
 LN8  Fatigue 
 
Adverse effects of Efavirenz 
 E1. Rash 
 E2. Headache 
 E4. Abnormal dreams 
 E5. Dizziness 
 E6. Insomnia 
 E7. Depression 
 E8. Nausea & Vomiting 
 E9. Gynaecomastia 
 E10. Elevated liver enzymes 
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Appendix 4: Namibia Institute of Pathology Haematological Reference Ranges 
Full Blood Count 
Test Male Ref ranges Females Ref Ranges 
White Cell Count 4.00 – 11.00 X10ˆ9/L 4.00 – 11.00 X10ˆ9/L 
Red Cell Count 4.20 – 6.50 X10ˆ12/L 3.80 – 5.40 X10ˆ12/L 
Haemoglobin 14.00 – 18.80 g/dL 12.00 – 16.90 g/dL 
Haematocrit 40.00 – 54 % 37.00 – 44.00 % 
Mean Cell Volume 80 – 100 fl 80 – 100 fl 
Mean Cell Haemoglobin 27.00 – 32.00 pg 27.00 – 32.00 pg 
Mean Cell Haemoglobin 
Concentration 
32.00 – 36.00 g/dL 32.00 – 36.00 g/dL 
Red Cell Distribution Width 0.00 – 16.00 % 0.00 – 16.00 % 
Platelets 150.00 – 400.00 X10ˆ9/L 150.00 – 400.00 X10ˆ9/L 
MPV 6.00 – 9.00 fl 6.00 – 9.00 fl 
 
Biochemistry 
Creatinine 62.00 – 106.00 umol/L 44 – 80 umol/L 
ALT 1 – 41 IU/L 1 – 41 IU/L 
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Appendix 5: Example of the data collection tool  
Data Collection tool 
C
li
en
t 
co
d
e 
A
g
e 
R
x
 R
eg
im
en
 
S
ex
 
Adverse Effects Reported (Every 3 Months) Average 
Reported 
Adherence 
level 
1  
ST 
28 1b M Quarters 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16   
Cd 4 count                   92 57 256   313       
Viral Load                             694     
ALT           50       50               
HB                   15   14           
WT                     48 50     49     
Co morbid HBSA- RPR-                               
INH                             INH INH   
CTX   CTX CTX CTX CTX CTX CTX CTX CTX CTX CTX CTX CTX CTX CTX     
FP                                   
WCC                                   
RCC                                   
HEMATOCRIT                                   
MCV                                   
MCHC                                   
RDW                                   
PLATLET           107                       
MPV                                   
ADHERE GOOD GOOD GOOD GOO
D 
GOO
D 
GOOD POOR GOOD GOOD GOOD GOOD GOOD GOOD GOOD GOOD GOOD   
Cd 4 %                                   
CREATIN                                   
Adverse 
Effects 
Reported 
                                  
                                  
                                  
 
 
 
 
 
